Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Disruptive Pharma ABOSTO:DPHA +0.83%4 Quick Ratio is 6.99 as of Jun. 2026, which is 82% above its 10-year median of 3.84. GuruFocus rates OSTO:DPHA with a GF Score™ of 4/100. Among 997 Drug Manufacturers companies, Disruptive Pharma AB ranks better than 77.63% on this metric.
Disruptive Pharma AB (OSTO:DPHA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Disruptive Pharma AB Quick Ratio Related Terms
Disruptive Pharma AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Disruptive Pharma AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Disruptive Pharma AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Disruptive Pharma AB Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Disruptive Pharma AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Disruptive Pharma AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Disruptive Pharma AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Disruptive Pharma AB (OSTO:DPHA) has a Quick Ratio of 6.99 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Disruptive Pharma AB and its competitors. This is 82% above median its historical median of 3.84. Over the past decade, Disruptive Pharma AB's Quick Ratio has ranged from 3.06 to 4.62. According to the industry distribution chart, Disruptive Pharma AB ranks #223 out of 997 companies in the Drug Manufacturers industry, placing it in the top 22.4%.
Is Disruptive Pharma AB's Quick Ratio too high?
Disruptive Pharma AB's current Quick Ratio of 6.99 is 82% above median its 10-year median of 3.84. Over the past 10 years, this metric has ranged from a low of 3.06 to a high of 4.62. The Drug Manufacturers industry median Quick Ratio is 1.40. Disruptive Pharma AB's value of 6.99 is 399.3% above this industry median. Based on the distribution chart, Disruptive Pharma AB ranks #223 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Disruptive Pharma AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Disruptive Pharma AB's Quick Ratio compare to ?
According to the Drug Manufacturers industry distribution chart, Disruptive Pharma AB ranks #223 out of 997 companies for Quick Ratio. This places Disruptive Pharma AB in the top 22% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.40. Disruptive Pharma AB's value of 6.99 is 399.3% above this benchmark. Historically, Disruptive Pharma AB's own Quick Ratio has ranged from 3.06 to 4.62 over the past decade. While the company's 10-year median is 3.84 vs. the industry median of 1.40, Disruptive Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.40, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Disruptive Pharma AB's current Quick Ratio of 6.99 is 399.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Disruptive Pharma AB and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Disruptive Pharma AB's current Quick Ratio is 6.99, which is 82% above median its own 10-year median of 3.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disruptive Pharma AB stock overvalued right now?
Disruptive Pharma AB (OSTO:DPHA) has a current Quick Ratio of 6.99. The current Quick Ratio is 6.99, which is 82% above median its 10-year median of 3.84 and 399.3% above the Drug Manufacturers industry median of 1.40. Disruptive Pharma AB's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Disruptive Pharma AB (OSTO:DPHA), the current Quick Ratio is 6.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Disruptive Pharma AB is a Swedish drug delivery technology company developing and commercializing Formulite, a patented platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company's business model is based on contract development, partnerships and licensing arrangements with pharmaceutical and biotechnology companies for the development and commercialization of drug products optimized with Formulite.
4GF Score
Get the complete analysis for OSTO:DPHA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DPHA has been successfully added to your 
